But this comes in second-line breast cancer, a use the group isn’t pursuing.
ApexOnco Front Page
Recent articles
The company admits defeat with zelenectide.
Early Ibtrozi sales and a low-cost licensing deal with Eisai disappoint investors.
Readout of the Pivot-006 trial is brought forward by nearly a year.
The company secures funding to push its lead candidate towards US approval.
Prexasertib data worsen again, and biomarkers are up in the air.
After Aktis's $318m flotation Eikon is a bigger proposition.
$650m buys the group rights to RemeGen’s RC148.
